Equity
AOCI
Alnylam Pharmaceuticals AOCI decreased by 23.9% to -$24.89M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 33.6%, from -$37.52M to -$24.89M. Over 5 years (FY 2020 to FY 2025), AOCI shows an upward trend with a -14.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryRisk
SignalContext dependent
VolatilityVolatile
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
Large negative values often reflect unfavorable currency movements or a decline in the market value of the company's investment portfolio.
Detailed definition
A component of equity that aggregates unrealized gains and losses that are excluded from net income. This typically incl...
Peer comparison
Multinational corporations with significant overseas operations and large cash portfolios are more sensitive to this metric than domestic-only firms.
Metric ID:
aociHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$36.08M | -$34.23M | -$33.26M | -$38.07M | -$42.22M | -$43.78M | -$44.65M | -$39.12M | -$37.08M | -$32.34M | -$23.38M | -$26.99M | -$34.64M | -$24.83M | -$34.52M | -$37.52M | -$29.95M | -$21.78M | -$20.10M | -$24.89M |
| QoQ Change | — | +5.1% | +2.8% | -14.5% | -10.9% | -3.7% | -2.0% | +12.4% | +5.2% | +12.8% | +27.7% | -15.5% | -28.3% | +28.3% | -39.0% | -8.7% | +20.2% | +27.3% | +7.7% | -23.9% |
| YoY Change | — | — | — | — | -17.0% | -27.9% | -34.3% | -2.8% | +12.2% | +26.1% | +47.7% | +31.0% | +6.6% | +23.2% | -47.7% | -39.0% | +13.5% | +12.3% | +41.8% | +33.6% |
Range-$44.65M – -$20.10M
CAGR-7.5%
Avg YoY Growth+5.0%
Median YoY Growth+12.2%
AOCI at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's aoci?
- Alnylam Pharmaceuticals (ALNY) reported aoci of -$24.89M in Q1 2026.
- How has Alnylam Pharmaceuticals's aoci changed year-over-year?
- Alnylam Pharmaceuticals's aoci increased by 33.6% year-over-year, from -$37.52M to -$24.89M.
- What is the long-term trend for Alnylam Pharmaceuticals's aoci?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's aoci has grown at a -14.4% compound annual growth rate (CAGR), from -$43.62M to -$20.10M.
- What does aoci mean?
- A bucket for 'paper' gains or losses on investments and currency changes that haven't been finalized yet.